Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: A subgroup analysis of the TRINITY study by age

Drugs and Aging

Volumn 30, Issue 7, 2013, Pages 549-560

  Lewin, Andrew J ^a   Izzo, Joseph L ^b   Melino, Michael ^c   Lee, James ^c   Fernandez, Victor ^c   Heyrman, Reinilde ^c  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE PLUS OLMESARTAN; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84879536533     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0072-1     Document Type: Article

References (49)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update - a report from the American Heart Association. Circulation. 2013;127(1):143-52.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
3. Yoon SS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008 [NCHS data brief, no. 48]. National Center for Health Statistics. http://www.cdc.gov/nchs/data/ databriefs/db48.pdf. Accessed 25 April 2011.
4. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents. J Am Coll Cardiol. 2011;57(20):2037-114.
5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.
6. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903- 13.
7. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-86.
8. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-52.
9. Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972-84.
10. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29.
11. Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009;10(12):1869-74.
12. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252-69.
13. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-54.
14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-64.
15. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5.
16. Staessen J. Mortality and treated blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. Am J Med. 1991;90(3A):60S-61S.
17. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304(6824):405-12.
18. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64.
19. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 Pt 1):1823-9.
20. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98.
21. Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028.
22. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung. 2011;61(4):221-8.
23. Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;8(11):2342-50.
24. Omboni S, Malacco E, Mallion JM, et al. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens. 2012;30(7):1468-77.
25. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
26. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
27. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-82.
28. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.
29. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869-78.
30. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
31. Chapman N, Chang CL, Dahlof B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42-8.
32. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11(8):411-21.
33. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich). 2010;12(1):3-13.
34. Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens. 2010;24(12):831-8.
35. Neutel J, Kereiakes DJ, Stoakes KA, et al. Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study. Drugs Aging. 2011;28(6):477-90.
36. Schmieder RE, Bohm M. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens. 2011;25(6):354-63.
37. Kereiakes DJ, Chrysant SG, Izzo JL Jr, et al. Olmesartan/amlodipine/ hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11(1):134.
38. Volpe M, Christian RL, Ammentorp B, et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32(10):649-64.
39. Jackson KC, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008;30(8):1558-63.
40. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243-9.
41. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3(6):999-1005.
42. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168(3):271-6.
43. Black HR. Triple fixed-dose combination therapy. Back to the past. Hypertension. 2009;54(1):19-22.
44. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-9.
45. Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin. 2008;24(9):2597-607.
46. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33(11):652-66.
47. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
48. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065-76.
49. Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26(12):2877-87.